Personalized Cancer Monitoring
Investigational liquid-biopsy based cancer recurrence detection
Clinicians are eager to expand precision oncology into early-stage cancer when the cancer is typically easier to cure compared to late-stage cancer.
Current monitoring methods, including imaging and cancer antigen tests, lack resolution and accuracy needed to monitor early-stage disease.1
Personalized Cancer Monitoring (PCM™)
We are developing the PCM technology as a minimally invasive and highly sensitive product that is informed by the patient’s tumor and is intended for monitoring cancer to expand precision oncology to early-stage cancer treatment and recurrence surveillance. Granted Breakthrough Device Designation by the U.S. FDA, Archer® PCM technology accesses circulating tumor DNA (ctDNA) from routine blood draws in an effective and non-invasive way to monitor cancer, which may inform the course of cancer treatment.
Our PCM solution is designed to detect disease burden, including minimal residual disease (MRD), because we manufacture patient-specific ctDNA panels based upon the genomic tumor profile of their individual cancer.
Personalized Cancer Monitoring (PCM™) Fact Sheet
- Hyman DM, et al. Implementing Genome-Driven Oncology. Cell. 2017;168(4):584‐599
- Chris Abbosh et al. Phylogenetic tracking and minimal residual disease detection using ctDNA in early-stage NSCLC: A lung TRACERx study. AACR Annual Meeting 2020 Virtual Meeting I, CT023
NOT APPROVED BY US FDA. NOT FOR DIAGNOSTIC USE. NOT FOR COMMERCIAL DISTRIBUTION.